Quick Answer
BioNexus Gene Lab Corp reported Total Assets of $10.43 million for the year ending 2024.
- BioNexus Gene Lab Corp showed a decrease of -8.5% in Total Assets from 2023 to 2024.
- This data is from BioNexus Gene Lab Corp's annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $1.61 million | Q2 2019: $1.51 million | Q3 2019: $1.34 million | Q1 2020: $1.13 million | Q2 2020: $1.06 million | Q3 2020: $1.01 million | Q1 2021: $9.90 million | Q2 2021: $9.45 million | Q3 2021: $9.77 million | Q1 2022: $9.18 million | Q2 2022: $8.37 million | Q3 2022: $7.80 million | Q1 2023: $8.19 million | Q2 2023: $7.90 million | Q1 2024: $11.16 million | Q2 2024: $11.14 million | Q3 2024: $11.00 million | Q4 2024: $10.43 million | Q1 2025: $9.48 million | Q2 2025: $9.42 million | Q3 2025: $7.62 million.
- Over the full 7 years of available data (2018 to 2024), BioNexus Gene Lab Corp's Total Assets has grown by 531.5%.
- Historical annual values: Fiscal year 2024: $10.43 million | Fiscal year 2023: $11.40 million | Fiscal year 2022: $8.74 million | Fiscal year 2021: $9.57 million | Fiscal year 2020: $10.12 million | Fiscal year 2019: $1.23 million | Fiscal year 2018: $1.65 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: